Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model

Journal of Pharmaceutical Sciences

Volumn 91, Issue 3, 2002, Pages 680-689

  Shibata, Nobuhito ^a   Gao, Weihua ^a   Okamoto, Hiroyuki ^a   Kishida, Tomoyuki ^a   Iwasaki, Koji ^a   Yoshikawa, Yukako ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

AIDS patient; Double protease therapy; HIV protease inhibitor; Pharmacokinetics interactions in rats; Physiologically based pharmacokinetic model

Indexed keywords

AMPRENAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; INTESTINE; INTESTINE ABSORPTION; LIVER; MALE; NONHUMAN; RAT;

EID: 0036281268     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10051     Document Type: Article

References (31)

1. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV, even in patients on effective combination therapy
2. Protease inhibitors in patients with HIV disease
3. Pharmacokinetics and potential interactions among anretroviral agents used to treat patients with HIV infection
4. Microcomputer programs for physiologically-based pharmacokinetic (PB-PK) modeling
5. Pharmacokinetic interactions between HIV-protease inhibitors in rats
6. Pharmacokinetic interaction between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors
7. In vitro and in vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats
8. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4
9. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: Evidence for the involvement of cytochrome P-450 3A subfamily
10. Physiologically based pharmacokinetics of drug-drug interaction: A study of tolbutamide-sulfonamide interaction in rats
11. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes
12. Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance
13. Time and dose dependence of 3-methylcholanthrene-induced metabolism in rat intestinal mucosal cells and microsomes
14. Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin
15. Physiologically based pharmacokinetic modeling: Principles and applications
16. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data
17. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans
18. Development and evaluation of plasma drug concentration simulation software based on Visual BASIC program "GRTORUN" for repeat dose noncompartmental pharmacokinetic analysis
19. A pharmacokinetic analysis program (MULTI) for microcomputer
20. Is the role of the small intestine in first-pass metabolism over-emphasized?
21. An information criterion (AIC)
22. Development and evaluation of noncompartmental pharmacokinetic analysis program 'WinHARMONY' using Visual BASIC language having a function of automatic recognition vs. time profile
23. Some suggestions for measuring predictive performance
24. Physiologically based pharmacokinetic study on a cyclosporine derivative, SDZ IMM125
25. Applications of physiologic pharmacokinetic modering in carcinogrenic risk assessment
26. A PC-based graphical simulator for physiological pharmacokinetic models
27. Drug exsorption from blood into the gastrointestinal tract
28. Dose dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat
29. In vitro disposition and metabilism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats
30. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
31. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir